trending Market Intelligence /marketintelligence/en/news-insights/trending/FIvShwAvZVpq0oCLsdHYpw2 content esgSubNav
In This List

Mesoblast heart drug clears interim phase 3 trial

Blog

Insight Weekly: US bank stress tests; cracks in housing market; summer energy supply risks

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches


Mesoblast heart drug clears interim phase 3 trial

Mesoblast Ltd.'s heart failure treatment MPC-150-IM was successful in an interim phase 3 trial.

Given the results, the trial's independent data monitoring committee said it had no safety concerns and that the trial should continue.

The trial is expected to enroll a total of about 600 patients, up from the trial's first 270 patients.